HGF/c MET Pathway in AIDS Related Lymphoma
Abstract
In the third year of funding period, we have completed Specific Aim 3, and have almost completed Specific Aim 1 and Specific Aim 2. So we have achieved respective milestones listed in the SOW forms. In this year, we focus on targeting HGF/c-MET regulated downstream genes, especially the ribonucleotide reductase subunit M2 (RRM2) in KSHV tumor cells. We have found that one of RRM2 inhibitors, 3-AP, actively induces PEL cell cycle arrest through inhibiting the activity of the NF-B pathway. 3-AP treatment effectively suppresses PEL progression in immunodeficient mice. Targeting RRM2 by 3-AP can also inhibit the growth of Kaposis Sarcoma (another type of cancer caused by KSHV) cells in vitro and in vivo. During this year funding period, we have totally published 9 peer-reviewed articles about the molecular mechanisms of KSHV viral oncogenesis, and developing novel therapeutic strategies against these malignancies (including one in press now). In most of these publications, I serve as the corresponding or co-corresponding author. We also have published several meeting abstracts on national or international meetings. With the support by this DOD award, I recently got a NIH/NCI RO1 funding (asPI) and a NIH COBRE subproject (as project leader).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2018
- Accession Number
- AD1064008
Entities
People
- Lu Dai
- Zhiqiang Qin
Organizations
- Louisiana State University